Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More

Earlier this year, it seemed that companies testing Alzheimer?s disease treatments based on a long-held hypothesis as to its cause?brain deposits of a protein called beta amyloid?were giving up the ghost. Biogen (NASDAQ: BIIB) was among them. The drug maker had stopped testing of a drug developed to target amyloid plaque after a Phase 3 [?]